2023
Domestic Violence-Related Ocular Injuries Among Adult Patients: Data from the Nationwide Emergency Department Sample, 2008–2017
Andoh J, Mehta S, Chen E, Mir T, Nwanyanwu K, Teng C. Domestic Violence-Related Ocular Injuries Among Adult Patients: Data from the Nationwide Emergency Department Sample, 2008–2017. Ophthalmic Epidemiology 2023, 31: 169-177. PMID: 37345877, PMCID: PMC10739625, DOI: 10.1080/09286586.2023.2222792.Peer-Reviewed Original ResearchNationwide Emergency Department SampleCommon ocular injuriesEye/adnexaOcular injuriesED visitsAdult emergency department patientsMost ED visitsMean hospital stayHospital admission ratesEmergency department patientsHospital-level variablesAnnual incidence rateEmergency Department SampleCross-sectional studyLowest income quartileHospital stayAdult patientsDepartment patientsHospital admissionOpen globeAdmission ratesIncidence rateRegional hospitalMean costOrbital fractures
2022
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Balasubramanian P, Wanner C, Ferreira J, Ofstad A, Elsaesser A, Zinman B, Inzucchi S. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? Medicine Of Ukraine 2022, 48-52. DOI: 10.37987/1997-9894.2022.5-6(261-2).271666.Peer-Reviewed Original ResearchIncidence rate ratiosT2D patientsClinical trialsStone eventsGLP-1 receptor agonistsLarge cardiovascular outcome trialsEMPA-REG OUTCOMESGLT2 inhibitor empagliflozinCardiovascular outcome trialsProspective clinical trialsSGLT2 inhibitor useRisk of nephrolithiasisAnnual incidence rateRandomized clinical trialsType 2 diabetesRelative risk estimatesEmpagliflozin therapyInhibitor empagliflozinInhibitor useOutcome trialsDiabetes mellitusSGLT2 inhibitionReceptor agonistRisk factorsIncidence rate
2019
The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease
Thakur ER, Sansgiry S, Kramer JR, Waljee AK, Gaidos JK, Feagins LA, Govani SM, Dindo L, El-Serag HB, Hou JK. The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2019, 26: 1423-1428. PMID: 31728520, PMCID: PMC7441098, DOI: 10.1093/ibd/izz280.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseasePrevalence of anxietyPosttraumatic stress disorderMental health problemsStress disorderBowel diseaseUS veteransIncidence rateChronicity of IBDHealth problemsAnnual incidence rateStress disorder diagnosisPosttraumatic stress disorder (PTSD) diagnosisPost-traumatic stress disorderPresence of anxietyIBD patientsStudy cohortNational cohortAnnual prevalenceDiagnosis incidenceDirect standardization methodGeneral populationPatientsPrior anxietyPrevalence
2017
Impact of PCV13 on Serotype 3 Invasive Pneumococcal Disease and Nasopharyngeal Carriage in Massachusetts’ Children
Lapidot R, Shea K, Little B, Yildirim I, Pelton S. Impact of PCV13 on Serotype 3 Invasive Pneumococcal Disease and Nasopharyngeal Carriage in Massachusetts’ Children. Open Forum Infectious Diseases 2017, 4: s467-s467. PMCID: PMC5631065, DOI: 10.1093/ofid/ofx163.1194.Peer-Reviewed Original ResearchPresence of comorbiditiesIPD casesPCV13 implementationYears of ageClinical syndromeSpeaker honorariaNP carriageNasopharyngeal carriageSerotype 3 invasive pneumococcal diseaseInvasive pneumococcal disease incidenceAge distributionEffectiveness of PCV13Impact of PCV13US census estimatesInvasive pneumococcal diseasePneumococcal disease incidenceAnnual incidence rateActive Surveillance NetworkAnnual prevalence rateIPD incidenceMerck vaccinePCV13 dosePneumococcal diseaseVaccination statusVaccine serotypes
2016
Incidence and Risk for Mood and Anxiety Disorders in a Representative Sample of Ohio Army National Guard Members, 2008–2012
Fink D, Chen Q, Liu Y, Tamburrino M, Liberzon I, Shirley E, Fine T, Cohen G, Galea S, Calabrese J. Incidence and Risk for Mood and Anxiety Disorders in a Representative Sample of Ohio Army National Guard Members, 2008–2012. Public Health Reports 2016, 131: 614-622. PMID: 27453607, PMCID: PMC4937124, DOI: 10.1177/0033354916662221.Peer-Reviewed Original ResearchConceptsAlcohol use disorderNational Guard membersPsychiatric disordersMood disordersArmy National Guard membersDepressive disorderUse disorderTraumatic eventsGuard membersIncident anxietyStructured Clinical InterviewIncidence rateDiscrete-time Cox proportional hazards modelsRisk factorsAnxiety disordersMilitary sampleClinical InterviewIncident disordersAnnual incidence rateHighest incidence rateCox proportional hazards modelsMoodPast-year experienceAnxietyPotential risk factorsA randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
Goss P, Ingle J, Pritchard K, Robert N, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff A, Winer E, Hudis C, Stopeck A, Beck J, Kaur J, Whelan K, Tu D, Parulekar W. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. Journal Of Clinical Oncology 2016, 34: lba1-lba1. DOI: 10.1200/jco.2016.34.18_suppl.lba1.Peer-Reviewed Original ResearchEarly-stage breast cancerYears of tamoxifenAromatase inhibitor therapyDisease-free survivalBreast cancerAI treatmentPostmenopausal womenInhibitor therapyHormone receptor-positive early breast cancerReceptor-positive early breast cancerTwo-sided log-rank testDisease-free survival eventsPositive early breast cancerPrior adjuvant chemotherapyPlacebo-controlled trialYear overall survivalContralateral breast cancerEarly breast cancerAnnual incidence rateStage breast cancerLog-rank testStandard of careBreast cancer recurrenceAdjuvant chemotherapyAdjuvant letrozoleExtending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal Of Medicine 2016, 375: 209-219. PMID: 27264120, PMCID: PMC5024713, DOI: 10.1056/nejmoa1604700.Peer-Reviewed Original ResearchConceptsContralateral breast cancerDisease-free survivalAromatase inhibitorsBreast cancerOverall survivalDisease-free survival ratesPositive early breast cancerAdjuvant aromatase inhibitorsNew-onset osteoporosisPlacebo-controlled trialPrimary end pointEarly breast cancerAnnual incidence rateTreatment of choiceBreast cancer recurrenceExtension of treatmentQuality of lifeBone painLetrozole groupAdjuvant therapyPlacebo groupPostmenopausal womenDisease recurrenceIncidence rateLower incidence
2005
Declining Incidence of Invasive Streptococcus pneumoniae Infections among Persons with AIDS in an Era of Highly Active Antiretroviral Therapy, 1995—2000
Heffernan RT, Barrett NL, Gallagher KM, Hadler JL, Harrison LH, Reingold AL, Khoshnood K, Holford TR, Schuchat A. Declining Incidence of Invasive Streptococcus pneumoniae Infections among Persons with AIDS in an Era of Highly Active Antiretroviral Therapy, 1995—2000. The Journal Of Infectious Diseases 2005, 191: 2038-2045. PMID: 15897989, DOI: 10.1086/430356.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal disease incidencePneumococcal disease incidenceInvasive Streptococcus pneumoniae infectionsInvasive pneumococcal diseaseStreptococcus pneumoniae infectionPneumococcal diseasePneumoniae infectionIncidence ratePre-HAART eraActive antiretroviral therapyAnnual incidence rateRange of subgroupsAnnual percentage changeYears of ageAIDS surveillance dataActive surveillance systemSan Francisco CountyRace/ethnicityTime trend analysisAntiretroviral therapyDisease incidence ratesAnnual incidenceImmunodeficiency syndromePersons 18High risk
2004
Hepatitis C incidence—a comparison between injection and noninjection drug users in New York City
Fuller C, Ompad D, Galea S, Wu Y, Koblin B, Vlahov D. Hepatitis C incidence—a comparison between injection and noninjection drug users in New York City. Journal Of Urban Health 2004, 81: 20-24. PMID: 15047780, PMCID: PMC3456148, DOI: 10.1093/jurban/jth084.Peer-Reviewed Original ResearchConceptsHepatitis C virusInjection drug usersNoninjection drug usersDrug usersHCV seropositiveRisk of HCVNew injection drug usersPerson-time analysisAnnual incidence rateHepatitis C incidenceAnnual incident rateHigh-risk practicesHCV incidenceHCV seroconvertersNon-IDUsHCV serologyHCV preventionC virusRisk factorsIncidence ratePrevention servicesOnset of injectionEarly preventionNew York CityRisk Survey
1997
Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland
Villano S, Vlahov D, Nelson K, Lyles C, Cohn S, Thomas D. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. Journal Of Clinical Microbiology 1997, 35: 3274-3277. PMID: 9399533, PMCID: PMC230161, DOI: 10.1128/jcm.35.12.3274-3277.1997.Peer-Reviewed Original ResearchConceptsInjection drug usersHCV infectionRisk factorsDrug usersDrug useDrug paraphernaliaHepatitis C virus infectionC virus infectionAnnual incidence rateActive drug useHigh-risk sexual practicesSharing of needlesHCV seroconversionHepatitis CAntibody testingOverall incidenceIncidence rateVirus infectionSerum samplesInfectionIncidenceHCVSexual practicesFrequent useParticipants
1996
Effect of Isoniazid Chemoprophylaxis on HIV-Related Mycobacterial Disease
Graham N, Galai N, Nelson K, Astemborski J, Bonds M, Rizzo R, Sheeley L, Vlahov D. Effect of Isoniazid Chemoprophylaxis on HIV-Related Mycobacterial Disease. JAMA Internal Medicine 1996, 156: 889-894. PMID: 8774208, DOI: 10.1001/archinte.1996.00440080089010.Peer-Reviewed Original ResearchConceptsM avium complexMycobacterial diseaseTuberculosis incidenceAvium complexCutaneous anergyIsoniazid chemoprophylaxisIsoniazid prophylaxisPreventive therapyRisk factorsIncidence rateCD4 lymphocyte cell countProspective observational cohort studyPPD-positive patientsTwice-weekly isoniazidWeeks of therapyObservational cohort studyLymphocyte cell countsMonths of diagnosisOverall incidence rateAnnual incidence ratePopulation-based dataStrong risk factorTuberculin-positive subjectsMycobacterium avium complexTuberculin-positive individuals
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply